Hostname: page-component-745bb68f8f-b6zl4 Total loading time: 0 Render date: 2025-01-07T12:20:08.223Z Has data issue: false hasContentIssue false
  • English
  • Français

Changes in the microbiology, epidemiology, and outcomes of candidemia in Connecticut: A comparison between two periods using statewide surveillance

Published online by Cambridge University Press:  25 August 2022

Johanna R. Gleason-Vergados ,
Paula Clogher Open the ORCID record for Paula Clogher [Opens in a new window] ,
James I. Meek  and
David B. Banach Open the ORCID record for David B. Banach [Opens in a new window]
Johanna R. Gleason-Vergados
Affiliation:
University of Connecticut School of Medicine, Farmington, Connecticut
Paula Clogher
Affiliation:
Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut
James I. Meek
Affiliation:
Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut
David B. Banach*
Affiliation:
University of Connecticut School of Medicine, Farmington, Connecticut
*
Author for correspondence: David B. Banach, E-mail: DBanach@uchc.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Using statewide surveillance, we describe candidemia in Connecticut during 1998–2000 and 2019. In 2019, candidemia was more frequently associated with community-onset and non-albicans Candida species and less frequently associated with central vascular catheters, recent surgery, and in-hospital mortality. Understanding changes in candidemia can optimize clinical management and prevention strategies.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 44 , Issue 6 , June 2023 , pp. 994 - 996
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION. Some of the information in this article was presented in an abstract at the Society of Healthcare Epidemiology of America Spring 2021 meeting on April 13–16. 2021, held virtually.

References

Morgan, J, Meltzer, MI, Plikaytis, BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540–547.10.1086/502581CrossRefGoogle ScholarPubMed
Guinea, J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 2014;20 suppl 6:5–10.CrossRefGoogle Scholar
Cheng, MF, Yang, YL, Yao, TJ, et al. Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis 2005;7;5:22.CrossRefGoogle Scholar
Morrell, M, Fraser, VJ, Kollef, MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640–3645.CrossRefGoogle ScholarPubMed
Hajjeh, RA, Sofair, AN, Harrison, LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519–1527.10.1128/JCM.42.4.1519-1527.2004CrossRefGoogle Scholar
Giacobbe, DR, Maraolo, AE, Simeon, V, et al. Changes in the relative prevalence of candidaemia due to non-albicans Candida species in adult in-patients: a systematic review, meta-analysis and meta-regression. Mycoses 2020;63:334–342.CrossRefGoogle ScholarPubMed
Suzuki, H, Perencevich, EN, Diekema, DJ, et al. Temporal trends of candidemia incidence rates and potential contributions of infection control initiatives over 18 years within the US Veterans’ Health Administration system: a joinpoint time-series analysis. Clin Infect Dis 2021;73:689–696.CrossRefGoogle Scholar
Zhang, AY, Shrum, S, Williams, S, et al. The changing epidemiology of candidemia in the United States: injection drug use as an increasingly common risk factor-active surveillance in selected sites, United States, 2014–2017. Clin Infect Dis 2020;71:1732–1737.CrossRefGoogle ScholarPubMed
Seagle, EE, Jackson, BR, Lockhart, SR, et al. The landscape of candidemia during the COVID-19 pandemic. Clin Infect Dis 2021 Jun 18:ciab562. doi: 10.1093/cid/ciab562.CrossRefGoogle Scholar
Weiner-Lastinger, LM, Pattabiraman, V, Konnor, RY, et al. The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: a summary of data reported to the National Healthcare Safety Network. Infect Control Hosp Epidemiol 2021. doi: 10.1017/ice.2021.362.CrossRefGoogle Scholar